PRCS Praecis Pharmaceuticals (MM)

PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced that it will report Third Quarter 2006 financial results on Thursday, November 9, 2006, before the financial markets open. Company management will host a conference call beginning at 9:00 a.m., EST, with members of the investment community. The Company�s conference call may be accessed live by visiting PRAECIS� website at http://www.praecis.com under �Investors� and �Webcast Live.� Interested parties also may listen to a replay of the call beginning Thursday, November 9, at 12:00 Noon, EST, until midnight Friday, November 17, by calling 888-203-1112 or 719-457-0820, and entering the passcode 6471068. PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds that have the potential to address unmet medical needs or improve existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkin�s lymphoma and solid tumors, as well as an innovative drug discovery technology, DirectSelect�, which enables the generation and practical use of ultra large libraries for the discovery of orally active compounds for drug development. PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced that it will report Third Quarter 2006 financial results on Thursday, November 9, 2006, before the financial markets open. Company management will host a conference call beginning at 9:00 a.m., EST, with members of the investment community. The Company's conference call may be accessed live by visiting PRAECIS' website at http://www.praecis.com under "Investors" and "Webcast Live." Interested parties also may listen to a replay of the call beginning Thursday, November 9, at 12:00 Noon, EST, until midnight Friday, November 17, by calling 888-203-1112 or 719-457-0820, and entering the passcode 6471068. PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds that have the potential to address unmet medical needs or improve existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug discovery technology, DirectSelect(TM), which enables the generation and practical use of ultra large libraries for the discovery of orally active compounds for drug development.